MedTrace Logo

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

NCT02094703 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2014-03-24

No results posted yet for this study

Summary

The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.

Conditions

Interventions

DRUG

Levofloxacin

DRUG

Solifenacin succinate

DRUG

Placebo (for Solifenacin succinate)

Sponsors & Collaborators

  • Astellas Pharma Indonesia Inc.

    collaborator INDUSTRY

  • Pharos Life Corporation

    collaborator INDUSTRY

  • Dr Cipto Mangunkusumo General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02094703 on ClinicalTrials.gov